--- title: "Natures Sunshine | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 122.89 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285624052.md" datetime: "2026-05-07T21:30:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285624052.md) - [en](https://longbridge.com/en/news/285624052.md) - [zh-HK](https://longbridge.com/zh-HK/news/285624052.md) --- # Natures Sunshine | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 122.89 M Revenue: As of FY2026 Q1, the actual value is USD 122.89 M, beating the estimate of USD 122.17 M. EPS: As of FY2026 Q1, the actual value is USD 0.29, beating the estimate of USD 0.205. EBIT: As of FY2026 Q1, the actual value is USD 9.506 M. #### Consolidated Performance Consolidated net sales for Nature’s Sunshine Products, Inc. increased by 8.5% to $122.9 million in 2026 from $113.2 million in 2025, or 6.9% in local currencies. Cost of sales increased to $32.9 million in 2026 from $31.6 million in 2025, but decreased as a percentage of net sales to 26.8% from 27.9% due to cost savings and market mix. Gross profit increased by 10.3% to $89.977 million in 2026 from $81.597 million in 2025, with the gross profit margin improving to 73.2% from 72.1%. Volume incentives expense rose by 5.9% to $36.893 million in 2026 from $34.844 million in 2025, though decreasing as a percentage of net sales to 30.0% from 30.8%. Selling, General and Administrative (SG&A) expenses increased by 7.3% to $43.539 million in 2026 from $40.581 million in 2025, while decreasing as a percentage of net sales to 35.4% from 35.8% due to reductions in professional fees, digital marketing, and other non-recurring expenses. Operating income increased by 54.7% to $9.545 million in 2026 from $6.172 million in 2025, with the operating income margin improving to 7.8% from 5.4%. Other income (expense), net, was - $1.4 million in 2026 compared to $0.9 million in 2025, primarily due to foreign exchange losses. Net income increased by 4.8% to $5.118 million in 2026 from $4.884 million in 2025. #### Segment Revenue - **Asia**: Net sales increased by 7.3% to $52.2 million in 2026 (5.9% in local currencies) from $48.7 million in 2025. - Taiwan: Net sales decreased by $2.9 million or 16.1% (19.3% in local currency). - Japan: Net sales increased by $1.4 million or 12.9% (16.0% in local currency). - South Korea: Net sales increased by $1.4 million or 13.4% (14.3% in local currency). - China: Net sales increased by $3.5 million or 45.7% (39.7% in local currency). - **Europe**: Net sales increased by 9.5% to $26.4 million in 2026 (6.0% in local currencies) from $24.1 million in 2025. - **North America**: Net sales increased by 9.4% to $38.3 million in 2026 (9.1% in local currencies) from $35.0 million in 2025. - United States: Net sales increased by $3.2 million or 9.7%. - **Latin America and Other**: Net sales increased by 9.7% to $6.0 million in 2026 (5.6% in local currencies) from $5.5 million in 2025. #### Segment Operating Income - **Asia**: Operating income was $10.485 million in 2026 compared to $8.345 million in 2025. - **Europe**: Operating income was $2.770 million in 2026 compared to $2.165 million in 2025. - **North America**: Operating income was $9.118 million in 2026 compared to $7.740 million in 2025. - **Latin America and Other**: Operating income was $0.723 million in 2026 compared to $0.387 million in 2025. #### Revenue by Product Category - **General health**: $49.070 million in 2026 vs. $45.924 million in 2025. - **Immune**: $10.145 million in 2026 vs. $10.275 million in 2025. - **Cardiovascular**: $20.341 million in 2026 vs. $20.513 million in 2025. - **Digestive**: $32.499 million in 2026 vs. $27.530 million in 2025. - **Personal care**: $6.977 million in 2026 vs. $4.548 million in 2025. - **Weight management**: $3.860 million in 2026 vs. $4.458 million in 2025. #### Cash Flow - **Operating Activities**: Used - $1.8 million in 2026 compared to provided $2.6 million in 2025, primarily due to timing differences in payments and receipts. - **Investing Activities**: Used - $2.5 million in 2026 compared to - $1.1 million in 2025, mainly for capital expenditures. - **Financing Activities**: Used - $1.6 million in 2026 compared to - $0.7 million in 2025. #### Other Key Metrics - **Working Capital**: $107.2 million as of March 31, 2026, up from $100.3 million as of December 31, 2025. - **Cash and Cash Equivalents**: $87.6 million as of March 31, 2026, with $84.0 million held in foreign markets. - **Share Repurchase Program**: Nature’s Sunshine Products, Inc. repurchased 20,000 shares for $0.5 million, with $16.9 million remaining available under the program as of March 31, 2026. - **Eastern Europe Operations**: Net sales were $17.6 million in 2026 compared to $15.8 million in 2025, with operating income of $2.0 million in 2026 compared to $1.4 million in 2025. - **China Joint Ventures**: Nature’s Sunshine Products, Inc. completed the purchase of Fosun Industrial’s interests in its two joint ventures on December 17, 2025, gaining 100% ownership. #### Future Outlook and Strategy Nature’s Sunshine Products, Inc. anticipates foreign currency exchange rates to materially impact sales and costs due to substantial foreign market operations. The company expects tariff-related price increases to adversely affect costs for the remainder of 2026. Management believes that cash generated from operations, along with available cash and cash equivalents, will be sufficient to fund both short- and long-term operating needs, including capital expenditures. ### Related Stocks - [NATR.US](https://longbridge.com/en/quote/NATR.US.md) ## Related News & Research - [Natures Sunshine Products's Earnings: A Preview](https://longbridge.com/en/news/278413534.md) - [Bunge shareholders approve annual dividend of $2.88 per share, paid quarterly at $0.72](https://longbridge.com/en/news/287115532.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md) - [Bally’s Corporation Reports First Quarter 2026 Results | BALY Stock News](https://longbridge.com/en/news/286814213.md)